Cancer news
Archived — this story has rotated out of today’s deck. It is kept here in full.
The gist
Moderna and Merck's mRNA melanoma vaccine cut death and metastasis risk in a Phase 3 trial. The win signals a broader shift toward personalized cancer vaccines.
Background
In mid-August 2026, Moderna and Merck announced positive results from a Phase 3 trial of their personalized mRNA cancer vaccine for melanoma, which lowered the risk of death and metastases. The vaccine primes the immune system to attack tumor cells by targeting neoantigens. This breakthrough has sparked a 'gold rush' in tumor sequencing and renewed interest in mRNA technology after a rough stretch.
How it unfolded
- mid-Aug 2026Moderna and Merck announced that a Phase 3 trial of their mRNA melanoma vaccine successfully lowered risk of death and metastases.
- Jul 20, 2026Tempus agreed to acquire Personalis for $16.25 per share, valuing the deal at $1.5 billion, positioning itself in the tumor sequencing space.
- recentlyThe companies plan to release full results at a European conference later this year, and similar trials are underway for kidney, lung, bladder, and squamous cell cancers.
Who’s saying what
- Analysts
- The success adds more than $50 billion in combined market value for Moderna and Merck, signaling strong commercial potential.
Still unverified
Full trial results have not yet been released; the companies only announced success. The vaccine's efficacy in other cancer types is still under investigation.